Compare VanEck Australian Floating Rate ETF (FLOT) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs Humana Inc — how do they compare? VanEck Australian Floating Rate ETF trades at $50.95 (market cap $11.24B), while Humana Inc trades at $435.54 (market cap $46.49B). The key difference: Humana Inc is far larger — about 4.1× VanEck Australian Floating Rate ETF's market cap, and Humana Inc pays a 0.91% dividend while VanEck Australian Floating Rate ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Australian Floating Rate ETF for 21 Days and Humana Inc for 53 Days on average.
| FLOT | HUM | |
|---|---|---|
Market Cap | $11.24B | $46.49B |
Volume | 1,872,962 | 2,567,704 |
Sector | Fixed Income | Health |
52-Week High | $51.07 | $409.85 |
52-Week Low | $50.72 | $163.67 |
Typical Hold Time | 21 Days | 53 Days |
Enterprise Value | — | $53.84B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.91 with minimal daily movement (-0.02%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. Recent dividend distributions of $0.17-$0.18 highlight income generation. The ETF benefits from floating rate exposure amid Fed tightening cycles, though concentration risk in bank holdings (47% exposure) warrants attention.
Outlook remains tied to interest rate trajectory, with FLOT positioned to benefit from higher rates. Key risks include bank sector concentration and Fed policy shifts. The current technical weakness suggests cautious near-term momentum despite the floating rate advantage in rising rate environments.
Humana (HUM) trades at $441.74, up 11.41% over 24 hours, reflecting strong momentum. The stock shows bullish technical signals with support at $391 and resistance at $406. Fundamentally, revenue grew to $129.66B in 2025, though net income margin compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and upcoming Q3 earnings on November 6, 2026.
The outlook is cautiously optimistic with a consensus price target of $457.05 implying modest upside. Risks include margin pressure from Medicare Advantage plan changes and potential regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
